Joanne Tan
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Joanne is a senior postdoctoral researcher at the South Australian Health and Medical Research Institute where she leads the miRNAs and Diabetes research programs in the Vascular Research Centre, Heart & Vascular Health Program, Lifelong Health Theme. She is also an Affiliate Senior Lecturer at The University of Adelaide. She is a vascular biologist with interests and expertise in angiogenesis and diabetes-impaired cellular mechanisms. She completed her PhD at The University of Sydney in 2007 where she looked at the role of adipocyte differentiation in the development of metabolic syndrome. She then began her postdoctoral training at the Heart Research Institute where she explored the vasculoprotective effects of high-density lipoproteins (HDL), with a particular focus on the role of HDL in angiogenesis-associated diseases. Her current research interests include exploring novel therapeutic targets that will alleviate vascular complications associated with diabetes.
Research Program: The prevalence of diabetes and its associated vascular complications are on the rise. Despite advances in management, many patients remain refractory to current treatments. As diabetes and its vascular complications impose a huge health and economic burden, highlighting a significant unmet clinical need for the discovery of new biomarkers that detect severity of disease and the development of novel treatments. MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression by targeting mRNAs causing either partial or complete translational repression. miRNAs have emerged as versatile targets for clinical therapeutics in complex multifaceted diseases such as diabetes and are the leading biopharmaceuticals in next generation medicine. miRNAs are stable in the circulation and studies have shown that miRNA profiles change with severity of disease. We have recently identified that the miRNA, miR-181c has novel anti-angiogenic properties and is important in diabetes-impaired angiogenic responses. Our group are seeking to explore whether miR-181c and other novel miRNA targets can act as both clinical biomarkers and therapeutic targets to alleviate the burden of diabetic vascular complications.
Research Project 1:
Title: miRNAs as clinical biomarkers for diabetic vascular complications
Project description: Circulating miRNAs have emerged as novel biomarkers and HDL miRNA content differs with disease states. Our preliminary data suggest that elevated HDL-bound miR-181c levels may be a novel biomarker reflective of diabetic vascular complications and provide insight into the extent of HDL functionality which may contribute to the impaired responses in diabetes seen in the Aboriginal population. Whether this biomarker is unique to the Aboriginal population or if the non-Indigenous population also have elevated HDL-miR-181c levels remains to be determined. We seek to assess whether circulating and HDL-bound miRNAs can serve as diagnostic biomarkers reflective of disease severity in different populations. We will comprehensively elucidate miRNA profiles in individuals without diabetes, with diabetes and with diabetes-associated vascular complications. Functional angiogenic capacity of the isolated HDL will be assessed using the Matrigel tubulogenesis assay in vitro and correlated with HDL miRNA profiles. This project will provide the opportunity to learn a broad range of techniques including HDL isolation, tissue culture, RNA isolation and qPCR.
Projects available for: Honours/HDR
Location: SAHMRI
Research Project 2:
Title: The use of high-density lipoproteins (HDL) as a novel theranostic miRNA delivery agent
Project description: There is growing evidence that targeted miRNA modulation is extremely feasible and may be more clinically effective in multifaceted diseases. Our preliminary findings suggest that miR-181c inhibition has significant promise to therapeutically reverse the impaired angiogenic response in diabetes. The biggest challenge in miRNA therapeutics is to safely and efficiently transport them to targeted cells and tissues. There is a switching focus for the use of HDL with the revelation of its emerging potential as a delivery agent. rHDL complexes composed of apolipoprotein (apo)A-I, the main protein component of HDL, and phospholipids can encapsulate drugs. Furthermore, HDL are known carriers of endogenous miRNAs, delivering them to recipient cells and imparting significant functional gene regulatory consequences. The use of HDL complexes to deliver miRNAs to prevent diabetic vascular complications has never been explored. This project will determine the efficacy of HDL-mediated delivery of miRNAs in endothelial cells in vitro and in and in vivo model of diabetic vascular complications. This project will provide the opportunity to learn a broad range of techniques including tissue culture, RT-PCR, Western blotting, HDL isolation and provide experience with an animal surgical model of angiogenesis.
Projects available for: Honours/HDR
Location: SAHMRI
-
Appointments
Date Position Institution name 2017 - ongoing Affiliate Senior Lecturer The University of Adelaide 2017 - ongoing Senior Postdoctoral Researcher South Australian Health and Medical Research Institute 2012 - ongoing Conjoint Lecturer The University of Sydney -
Language Competencies
Language Competency English Can read, write, speak, understand spoken and peer review Malay Can read, write, speak and understand spoken -
Education
Date Institution name Country Title The University of Sydney Australia PhD Monash University Australia BSc (Biotechnology) (Hons) -
Postgraduate Training
Date Title Institution Country 2011 - 2016 Senior Research Officer The Heart Research Institute Australia 2007 - 2010 Research Officer The Heart Research Institute Australia -
Research Interests
-
Journals
Year Citation 2024 Wong, N. K. P., Solly, E. L., Le, R., Nankivell, V. A., Mulangala, J., Psaltis, P. J., . . . Tan, J. T. M. (2024). TRIM2 Selectively Regulates Inflammation-Driven Pathological Angiogenesis without Affecting Physiological Hypoxia-Mediated Angiogenesis. International Journal of Molecular Sciences, 25(6), 16 pages.
2023 Santovito, D., Fan, Y., Elia, L., Tan, J. T. M., & van der Vorst, E. P. C. (2023). Editorial: Emerging roles of miRNAs in cardiovascular disease. Frontiers in Cardiovascular Medicine, 10, 1144849.
2023 Schwarz, N., Fernando, S., Chen, Y. -C., Salagaras, T., Rao, S. R., Liyanage, S., . . . Psaltis, P. J. (2023). Colchicine exerts anti-atherosclerotic and -plaque-stabilizing effects targeting foam cell formation. The FASEB Journal, 37(4), 1-20.
Scopus9 WoS2 Europe PMC42022 Chapman, N., Thomas, E. E., Tan, J. T. M., Inglis, S. C., Wu, J. H. Y., Climie, R. E., . . . Marques, F. Z. (2022). A roadmap of strategies to support cardiovascular researchers: from policy to practice. Nature reviews. Cardiology, 19(11), 765-777.
Scopus5 WoS3 Europe PMC22022 Shearston, K., Tan, J. T. M., Cochran, B. J., & Rye, K. A. (2022). Inhibition of Vascular Inflammation by Apolipoprotein A-IV. Frontiers in Cardiovascular Medicine, 9, 901408.
Scopus4 Europe PMC22022 Thomas, E., Chapman, N., de Camargo Catapan, S., Climie, R., Wise, S., Mirabito Colafella, K., . . . Marques, F. (2022). Strategies to support early- and mid-career cardiovascular researchers to thrive.
2022 Fernando, S., Salagaras, T., Schwarz, N., Sandeman, L., Tan, J. T. M., Xie, J., . . . Psaltis, P. J. (2022). Eukaryotic elongation factor 2 kinase regulates foam cell formation via translation of CD36. The FASEB Journal, 36(2), 1-19.
Scopus2 WoS3 Europe PMC12022 Mulangala, J., Akers, E. J., Solly, E. L., Bamhare, P. M., Wilsdon, L. A., Wong, N. K. P., . . . Di Bartolo, B. A. (2022). Pro-Calcific Environment Impairs Ischaemia-Driven Angiogenesis.. International journal of molecular sciences, 23(6), 1-21.
2022 Shin, J., Zhou, X., Tan, J. T. M., Hyppönen, E., Benyamin, B., & Lee, S. H. (2022). Lifestyle Modifies the Diabetes-Related Metabolic Risk, Conditional on Individual Genetic Differences. Frontiers in Genetics, 13, 759309-1-759309-10.
Scopus4 WoS4 Europe PMC42021 Williamson, A., Liyanage, S., Hassanshahi, M., Dona, M. S. I., Deborah, T. -F., Tran, D. X. A., . . . Psaltis, P. (2021). Discovery of embryonically derived bipotent endothelial-macrophage progenitor cells in postnatal aorta.
2021 Morrison, K. R., Solly, E. L., Shemesh, T., Psaltis, P. J., Nicholls, S. J., Brown, A., . . . Tan, J. T. M. (2021). Elevated HDL-bound miR-181c-5p level is associated with diabetic vascular complications in Australian Aboriginal people. Diabetologia, 64(6), 1402-1411.
Scopus12 WoS11 Europe PMC102021 Pisaniello, A. D., Psaltis, P. J., King, P. M., Liu, G., Gibson, R. A., Tan, J. T. M., . . . Di Bartolo, B. A. (2021). Omega-3 fatty acids ameliorate vascular inflammation: a rationale for their atheroprotective effects. Atherosclerosis, 324, 27-37.
Scopus24 WoS22 Europe PMC132021 Nankivell, V. A., Tan, J. T. M., Wilsdon, L. A., Morrison, K. R., Bilu, C., Psaltis, P. J., . . . Brown, A. (2021). Circadian disruption by short light exposure and a high energy diet impairs glucose tolerance and increases cardiac fibrosis in Psammomys obesus. Scientific reports, 11(1), 1-13.
Scopus10 WoS7 Europe PMC42021 Solly, E. L., Psaltis, P. J., Bursill, C. A., & Tan, J. T. M. (2021). The Role of miR-181c in Mechanisms of Diabetes-Impaired Angiogenesis: An Emerging Therapeutic Target for Diabetic Vascular Complications. Frontiers in Pharmacology, 12, 718679-1-718679-16.
Scopus11 WoS6 Europe PMC32021 Ravindran, D., Galougahi, K. K., Tan, J. T. M., Kavurma, M. M., & Bursill, C. A. (2021). The Multiple Roles of Chemokines in the Mechanisms of Stent Biocompatibility.. Cardiovasc Res, 117(11), 2299-2308.
Scopus4 Europe PMC22020 Climie, R. E., Wu, J. H. Y., Calkin, A. C., Chapman, N., Inglis, S. C., Mirabito Colafella, K. M., . . . Australian Cardiovascular Alliance. (2020). Lack of strategic funding and long-term job security threaten to have profound effects on cardiovascular researcher retention in Australia. Heart, Lung and Circulation, 29(11), 1588-1595.
Scopus9 WoS6 Europe PMC62020 Primer, K. R., Psaltis, P. J., Tan, J. T. M., & Bursill, C. A. (2020). The Role of High-Density Lipoproteins in Endothelial Cell Metabolism and Diabetes-Impaired Angiogenesis.. Int J Mol Sci, 21(10), 1-21.
Scopus18 WoS16 Europe PMC152020 Shin, J., Zhou, X., Tan, J., Hyppönen, E., Benyamin, B., & Lee, H. (2020). Lifestyle modifies the diabetes-related metabolic risk, conditional on individual genetic differences.
2019 Yuan, J., Tan, J. T. M., Rajamani, K., Solly, E. L., King, E. J., Lecce, L., . . . Ng, M. K. C. (2019). Fenofibrate rescues diabetes-related impairment of ischemia-mediated angiogenesis by PPARα-independent modulation of thioredoxin-interacting protein. Diabetes, 68(5), 1040-1053.
Scopus19 WoS15 Europe PMC112019 Tan, J. T. M., Nankivell, V. A., Bilu, C., Shemesh, T., Nicholls, S. J., Zimmet, P., . . . Bursill, C. A. (2019). High-Energy Diet and Shorter Light Exposure Drives Markers of Adipocyte Dysfunction in Visceral and Subcutaneous Adipose Depots of Psammomys obesus.. Int J Mol Sci, 20(24), 17 pages.
Scopus9 WoS8 Europe PMC72019 Solly, E. L., Dimasi, C. G., Bursill, C. A., Psaltis, P. J., & Tan, J. T. M. (2019). MicroRNAs as therapeutic targets and clinical biomarkers in atherosclerosis. Journal of Clinical Medicine, 8(12), 2199-1-2199-26.
Scopus46 WoS41 Europe PMC272019 MacEr-Wright, J. L., Stanley, N. R., Portman, N., Tan, J. T., Bursill, C., Rayner, B. S., & Hawkins, C. L. (2019). A role for chlorinated nucleosides in the perturbation of macrophage function and promotion of inflammation. Chemical Research in Toxicology, 32(6), 1223-1234.
Scopus12 WoS6 Europe PMC42019 Nguyen, M. T., Fernando, S., Schwarz, N., Tan, J. T. M., Bursill, C. A., & Psaltis, P. J. (2019). Inflammation as a therapeutic target in atherosclerosis. Journal of Clinical Medicine, 8(8), 1109-1-1109-20.
Scopus122 WoS99 Europe PMC622018 Ridiandries, A., Tan, J. T. M., & Bursill, C. A. (2018). The role of chemokines in wound healing. International Journal of Molecular Sciences, 19(10), 20 pages.
Scopus264 WoS209 Europe PMC1462018 Cannizzo, C. M., Adonopulos, A. A., Solly, E. L., Ridiandries, A., Vanags, L. Z., Mulangala, J., . . . Tan, J. T. (2018). VEGFR2 is activated by high-density lipoproteins and plays a key role in the proangiogenic action of HDL in ischemia. FASEB Journal, 32(6), 2911-2922.
Scopus10 WoS8 Europe PMC72018 Vanags, L. Z., Tan, J. T. M., Galougahi, K. K., Schaefer, A., Wise, S. G., Murphy, A., . . . Bursill, C. A. (2018). Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype. JACC: Basic to Translational Science, 3(2), 200-209.
Scopus17 WoS12 Europe PMC122018 Morton, J., Bao, S., Vanags, L., Tsatralis, T., Ridiandries, A., Siu, C., . . . Bursill, C. (2018). Strikingly different atheroprotective effects of apolipoprotein A-I in early- versus late-stage atherosclerosis. JACC: Basic to Translational Science, 3(2), 187-199.
Scopus14 WoS11 Europe PMC112018 Wong, N., Nicholls, S., Tan, J., & Bursill, C. (2018). The role of high-density lipoproteins in diabetes and its vascular complications. International Journal of Molecular Sciences, 19(6), 21 pages.
Scopus42 WoS29 Europe PMC292018 Wong, N. K. P., Cheung, H., Solly, E. L., Vanags, L. Z., Ritchie, W., Nicholls, S. J., . . . Tan, J. T. M. (2018). Exploring the roles of CREBRF and TRIM2 in the regulation of angiogenesis by high-density lipoproteins. International Journal of Molecular Sciences, 19(7), 1903-1-1903-17.
Scopus13 WoS13 Europe PMC82018 Hourigan, S. T., Solly, E. L., Nankivell, V. A., Ridiandries, A., Weimann, B., Henriquez, R., . . . Tan, J. T. M. (2018). The regulation of miRNAs by reconstituted high-density lipoproteins in diabetes-impaired angiogenesis. Scientific Reports, 8(1), 13596.
Scopus21 WoS13 Europe PMC162017 Vanags, L. Z., Tan, J. T. M., Santos, M., Michael, P. S., Ali, Z., Bilek, M. M. M., . . . Bursill, C. A. (2017). Plasma activated coating immobilizes apolipoprotein A-I to stainless steel surfaces in its bioactive form and enhances biocompatibility. Nanomedicine: Nanotechnology, Biology, and Medicine, 13(7), 2141-2150.
Scopus8 WoS7 Europe PMC42017 McRobb, L. S., McGrath, K. C. Y., Tsatralis, T., Liong, E. C., Tan, J. T. M., Hughes, G., . . . Heather, A. K. (2017). Estrogen Receptor Control of Atherosclerotic Calcification and Smooth Muscle Cell Osteogenic Differentiation. Arteriosclerosis, Thrombosis, and Vascular Biology, 37(6), 1127-1137.
Scopus40 WoS38 Europe PMC242017 Ridiandries, A., Bursill, C., & Tan, J. (2017). Broad-spectrum inhibition of the CC-chemokine class improves wound healing and wound angiogenesis. International Journal of Molecular Sciences, 18(1), 155-1-155-15.
Scopus28 WoS23 Europe PMC152017 Ridiandries, A., Tan, J., Ravindran, D., Williams, H., Medbury, H., Lindsay, L., . . . Bursill, C. (2017). CC-chemokine class inhibition attenuates pathological angiogenesis while preserving physiological angiogenesis. FASEB Journal, 31(3), 1179-1192.
Scopus14 WoS12 Europe PMC122017 Tan, J. T. M., Prosser, H. C. G., Dunn, L. L., Vanags, L. Z., Ridiandries, A., Tsatralis, T., . . . Bursill, C. A. (2017). High-Density Lipoproteins Rescue Diabetes-Impaired Angiogenesis via Scavenger Receptor Class B Type I (vol 65, pg 3091, 2016). DIABETES, 66(4), 1 page.
Europe PMC12017 Ravindran, D., Ridiandries, A., Vanags, L., Henriquez, R., Cartland, S., Tan, J., & Bursill, C. (2017). Chemokine binding protein 'M3' limits atherosclerosis in apolipoprotein E-/- mice. PLoS ONE, 12(3), e0173224-1-e0173224-23.
Scopus15 WoS14 Europe PMC92016 Lam, Y., Lecce, L., Tan, J., Bursill, C., Handelsman, D., & Ng, M. (2016). Androgen receptor-mediated genomic androgen action augments ischemia-induced neovascularization. Endocrinology, 157(12), 4853-4864.
Scopus6 WoS6 Europe PMC42016 Tsatralis, T., Ridiandries, A., Robertson, S., Vanags, L., Lam, Y., Tan, J. T., . . . Bursill, C. (2016). Reconstituted high-density lipoproteins promote wound repair and blood flow recovery in response to ischemia in aged mice. Lipids in Health and Disease, 15(1), 150-1-150-12.
Scopus16 WoS8 Europe PMC92016 Ridiandries, A., Tan, J., & Bursill, C. (2016). The role of CC-chemokines in the regulation of angiogenesis. International Journal of Molecular Sciences, 17(11), 1856-1-1856-16.
Scopus80 WoS70 Europe PMC602016 Tan, J., Prosser, H., Dunn, L., Vanags, L., Ridiandries, A., Tsatralis, T., . . . Bursill, C. (2016). High-density lipoproteins rescue diabetes-impaired angiogenesis via scavenger receptor Class B Type I. Diabetes, 65(10), 3091-3103.
Scopus35 WoS27 Europe PMC272016 Arnott, C., Punnia-Moorthy, G., Tan, J., Sadeghipour, S., Bursill, C., & Patel, S. (2016). The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells. PLOS ONE, 11(3), e0150688.
Scopus21 WoS23 Europe PMC142015 Tan, J., Ng, M., & Bursill, C. (2015). The role of high-density lipoproteins in the regulation of angiogenesis. Cardiovascular Research, 106(2), 184-193.
Scopus32 WoS29 Europe PMC222014 Prosser, H., Tan, J., Dunn, L., Patel, S., Vanags, L., Bao, S., . . . Bursill, C. (2014). Multifunctional regulation of angiogenesis by high-density lipoproteins. Cardiovascular Research, 101(1), 145-154.
Scopus42 WoS38 Europe PMC322014 Tan, J., Hamish, H., Vanags, L., Monger, S., Ng, M., & Bursill, C. (2014). High-density lipoproteins augment hypoxia-induced angiogenesis via regulation of post-translational modulation of hypoxia-inducible factor 1α. FASEB Journal, 28(1), 206-217.
Scopus48 WoS42 Europe PMC372014 McGrath, K. C., Li, X. H., Whitworth, P. T., Kasz, R., Tan, J. T., McLennan, S. V., . . . Heather, A. K. (2014). High density lipoproteins improve insulin sensitivity in high-fat diet-fed mice by suppressing hepatic inflammation. Journal of Lipid Research, 55(3), 421-430.
Scopus35 WoS34 Europe PMC282013 Tan, J. T. M., McLennan, S. V., Williams, P. F., Rezaeizadeh, A., Lo, L. W. Y., Bonner, J. G., & Twigg, S. M. (2013). Connective tissue growth factor/CCN-2 is upregulated in epididymal and subcutaneous fat depots in a dietary-induced obesity model.. American journal of physiology. Endocrinology and metabolism, 304(12), E1291-E1302.
Scopus20 WoS19 Europe PMC152013 Dunn, L., Prosser, H., Tan, J., Vanags, L., Ng, M., & Bursill, C. (2013). Murine model of wound healing. Journal of visualized experiments : JoVE, (75), e50265.
Scopus442013 Dunn, L., Prosser, H., Tan, J., Vanags, L., Ng, M., & Bursill, C. (2013). Murine model of wound healing. Journal of Visualized Experiments, 2013(75), 1-6.
Scopus184 WoS156 Europe PMC822011 Di Bartolo, B., Vanags, L., Tan, J., Bao, S., Rye, K., Barter, P., & Bursill, C. (2011). The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit.. Lipids in health and disease, 10(1), 224.
Scopus27 WoS24 Europe PMC162011 Moheimani, F., Tan, J. T. M., Brown, B. E., Heather, A. K., Van Reyk, D. M., & Davies, M. J. (2011). Effect of exposure of human monocyte-derived macrophages to high, versus normal, glucose on subsequent lipid accumulation from glycated and acetylated low-density lipoproteins. Experimental Diabetes Research, 2011, 10 pages.
Scopus11 WoS11 Europe PMC82010 Lane, A. E., Tan, J. T. M., Hawkins, C. L., Heather, A. K., & Davies, M. J. (2010). The myeloperoxidase-derived oxidant HOSCN inhibits protein tyrosine phosphatases and modulates cell signalling via the mitogen-activated protein kinase (MAPK) pathway in macrophages. Biochemical Journal, 430(1), 161-169.
Scopus75 WoS68 Europe PMC482010 Soosai, J., Ward, L., & Ziaian, T. (2010). Experiences of Chinese immigrants and Anglo-Australians ageing in Australia: A cross-cultural perspective on successful ageing. Journal of Health Psychology, 15(5 Sp Iss), 697-706.
Scopus26 WoS21 Europe PMC122009 McGrath, K. C. Y., Li, X. H., Puranik, R., Liong, E. C., Tan, J. T. M., Dy, V. M., . . . Heather, A. K. (2009). Role of 3β-hydroxysteroid-Δ24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(6), 877-882.
Scopus80 WoS76 Europe PMC582008 Tan, J. T. M., McLennan, S. V., Song, W. W., Lo, L. W. Y., Bonner, J. G., Williams, P. F., & Twigg, S. M. (2008). Connective tissue growth factor inhibits adipocyte differentiation. American Journal of Physiology - Cell Physiology, 295(3), C740-C751.
Scopus81 WoS76 Europe PMC622007 Lim, C. K., Tan, J. T. M., Ravichandran, A., Chan, Y. C., & Ton, S. H. (2007). Comparison of PCR-based genotyping methods for hepatitis B virus.. The Malaysian journal of pathology, 29(2), 79-90.
Europe PMC32006 Chee, K. L., Tan, J. T. M., Khoo, J. B. S., Ravichandran, A., Hsin, M. L., Yin, C. C., & So, H. T. (2006). Correlations of HBV genotypes, mutations affecting HBeAg expression and HBeAg/anti-HBe status in HBV carriers. International Journal of Medical Sciences, 3(1), 14-20.
Scopus22 Europe PMC17 -
Conference Papers
Year Citation 2022 Solly, E. L., Mulangala, J., Di Bartolo, B. A., Nicholls, S. J., Psaltis, P. J., Bursill, C. A., & Tan, J. T. M. (2022). Inhibition of microRNA-181c rescues diabetes-impaired angiogenesis through activation of key angiogenesis mediators. In DIABETOLOGIA Vol. 65 (pp. S25-S26). Stockholm, SWEDEN: SPRINGER. 2019 Morrison, K. R., Bursill, C., Solly, E., Shemesh, T., Nicholls, S., Brown, A. D., & Tan, J. T. M. (2019). HDL miR-181c as a Novel Biomarker for Diabetic Vascular Complications in Australian Aboriginal People. In DIABETES Vol. 68 (pp. 2 pages). San Francisco, CA: AMER DIABETES ASSOC.
WoS12019 Pisaniello, A. D., King, P., Di Bartolo, B. A., Liu, G., Gibson, R. A., Tan, J. T. M., . . . Nicholls, S. (2019). IMPACT OF FISH OIL SUPPLEMENTATION ON ACUTE VASCULAR INFLAMMATION IN HEALTHY VOLUNTEERS. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Vol. 73 (pp. 2091). New Orleans, LA: ELSEVIER SCIENCE INC.
2019 Mulangala, J., Akers, E., Solly, E. L., Bamhare, P. M., Wilsdon, L. A., Tan, J. T., . . . DiBartolo, B. A. (2019). Elevated Calcium Drives Ischemia-Induced Angiogenesis. In CIRCULATION Vol. 140 (pp. 2 pages). Philadelphia, PA: LIPPINCOTT WILLIAMS & WILKINS. 2017 Cannizzo, C. M., Adonopulos, A. A., Ridiandries, A., Vanags, L. Z., Yuen, S. C. G., Tsatralis, T., . . . Tan, J. T. (2017). VEGFR2 is Activated by High-Density Lipoproteins and Plays a Key Role in the Pro-Angiogenic Action of HDL in Ischemia. In CIRCULATION Vol. 136 (pp. 1 page). Anaheim, CA: LIPPINCOTT WILLIAMS & WILKINS. 2017 Hourigan, S. T., Ridiandries, A., Tepper, E. R., Zhang, J. Q., Henriquez, R., Tsatralis, T., . . . Tan, J. T. (2017). The Regulation of miRNAs in rHDL-Induced Rescue of Diabetes-Impaired Angiogenesis. In CIRCULATION Vol. 136 (pp. 1 page). Anaheim, CA: LIPPINCOTT WILLIAMS & WILKINS. 2014 Vanags, L., Tan, J., Wise, S., Ali, Z., & Bursill, C. (2014). ApoA-I Suppresses Neointimal Hyperplasia Following Stent Deployment and Modulates Neointimal Cellular Phenotype. In CIRCULATION Vol. 130 (pp. 2 pages). LIPPINCOTT WILLIAMS & WILKINS. 2014 Vanags, L. Z., Tan, J., Michael, J., Bilek, M., Wise, S., & Bursill, C. (2014). Immobilised apoA-I and High-Density Lipoproteins are Anti-Thrombotic and Exert Anti-Inflammatory Effects in Vascular Smooth Muscle Cells. In CIRCULATION Vol. 130 (pp. 2 pages). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2014 Macer-Wright, J., Stanley, N., Tan, J., Bursill, C., & Hawkins, C. (2014). Chlorinated Nucleosides - Novel Mediators or Biomarkers of Disease?. In FREE RADICAL BIOLOGY AND MEDICINE Vol. 76 (pp. S45-S46). ELSEVIER SCIENCE INC.
2014 Vanags, L., Tan, J., Michael, J., Bilek, M., Wise, S., & Bursill, C. (2014). STAINLESS STEEL-BOUND APOA-I AND RECONSTITUTED HIGH-DENSITY LIPOPROTEINS ARE ANTI-THROMBOTIC AND CAUSE ANTI-INFLAMMATORY EFFECTS IN HUMAN VASCULAR SMOOTH MUSCLE CELLS. In HYPERTENSION Vol. 63 (pp. E172-E173). Melbourne, AUSTRALIA: LIPPINCOTT WILLIAMS & WILKINS.
WoS12013 Macer-Wright, J., Stanley, N., Tan, J., Bursill, C., & Hawkins, C. (2013). Role of Chlorinated Nucleosides Produced by Hypochlorous Acid in the Perturbation of Cellular Function under Inflammatory Conditions. In FREE RADICAL BIOLOGY AND MEDICINE Vol. 65 (pp. S143). ELSEVIER SCIENCE INC.
2010 Lane, A. E., Tan, J. T. M., Hawkins, C. L., Heather, A. K., & Davies, M. J. (2010). The Myeloperoxidase-derived Oxidant HOSCN Inhibits Protein Tyrosine Phosphatases and Modulates Cell Signalling via the Mitogen-activated Protein Kinase (MAPK) Pathway in Macrophages. In FREE RADICAL BIOLOGY AND MEDICINE Vol. 49 (pp. S129). Orlando, FL: ELSEVIER SCIENCE INC.
WoS12009 Lane, A. E., Tan, J., Hawkins, C. L., Heather, A. K., & Davies, M. J. (2009). The Myeloperoxidase-Derived Oxidant HOSCN Inhibits Protein Tyrosine Phosphatases and Modulates Cell Signalling via the MAPK Pathway in Macrophages. In FREE RADICAL BIOLOGY AND MEDICINE Vol. 47 (pp. S42-S43). San Francisco, CA: ELSEVIER SCIENCE INC. 2009 Heather, A. K., Li, X. -H., Bartusch, M., Dy, V., Liong, E. C., McGrath, K. C., & Tan, J. T. (2009). DHCR24 Is a Negative Regulator of Nuclear Factor-κB and Chronic Inflammation in Human Endothelial Cells. In ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY Vol. 29 (pp. E27-E28). Washington, DC: LIPPINCOTT WILLIAMS & WILKINS. 2009 Tan, J., Li, X. -H., Bartusch, M., Dy, V., Liong, E., McGrath, K., . . . Heather, A. (2009). LOW DHCR24 LEVELS ARE ASSOCIATED WITH CHRONIC INFLAMMATION AND APOPTOSIS IN HUMAN ENDOTHELIAL CELLS. In ATHEROSCLEROSIS SUPPLEMENTS Vol. 10 (pp. 1 page). ELSEVIER IRELAND LTD. 2009 McRobb, L., Liong, E., Tan, J., & Heather, A. (2009). THE ROLE OF ESTROGEN RECEPTORS ALPHA AND BETA IN ATHEROSCLEROTIC LESION CALCIFICATION IN APOLIPOPROTEIN E-NULL MICE. In ATHEROSCLEROSIS SUPPLEMENTS Vol. 10 (pp. 1 page). ELSEVIER IRELAND LTD. 2009 Liong, E., McGrath, K., Tan, J., Li, X. -H., Dy, V., Barter, P., . . . Heather, A. (2009). ROLE OF 3B-HYDROXYSTEROID-[DELTA]24 REDUCTASE IN MEDIATING THE ANTI-INFLAMMATORY EFFECTS OF HIGH-DENSITY LIPOPROTEINS IN ENDOTHELIAL CELLS. In ATHEROSCLEROSIS SUPPLEMENTS Vol. 10 (pp. 1 page). ELSEVIER IRELAND LTD. 2008 Akeefe, H., Maltais, J. -A. B., Murphy, A., Chin-Dusting, J., Sviridov, D., Heather, A., . . . Brewer, H. B. (2008). An Apo A-I mimetic peptide LSI-518P exhibits ABCA1-specific efflux and anti-inflammatory properties. In ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY Vol. 28 (pp. E92). Atlanta, GA: LIPPINCOTT WILLIAMS & WILKINS.
WoS2 -
Conference Items
Year Citation 2022 Nankivell, V. A., Vidanapathirana, A., Rajora, M., Psaltis, P., Tan, J. T., Tieu, W., . . . Bursill, C. A. (2022). Theranostic Properties of Porphysome Nanoparticles in Atherosclerotic Cardiovascular Disease. Poster session presented at the meeting of CIRCULATION. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2022 Primer, K. R., Tan, J. T., Psaltis, P. J., & Bursill, C. A. (2022). Pyruvate Dehydrogenase Kinase 4 is a Novel Regulator of Endothelial Cell Mitochondrial Respiration in Diabetes-Impaired Angiogenesis: Implications for Preventing Diabetic Vascular Complications. Poster session presented at the meeting of CIRCULATION. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2022 Lotfollahi, Z., Tan, J. T., Dawson, J., Fitridge, R., & Bursill, C. A. (2022). Tracking High-Density Lipoprotein Functionality in Diabetic and Non-Diabetic Patients With Toe Amputations. Poster session presented at the meeting of CIRCULATION. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2022 Pullen, B. J., Vidanapathirana, A. K., Sandeman, L., Everest-Dass, A., Kolarich, D., Tan, J. T., . . . Bursill, C. A. (2022). Deletion of the Asialyloglycoprotein Receptor-1 Causes Athero-Protective Effects in vitro and in vivo. Poster session presented at the meeting of CIRCULATION. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2020 Pisaniello, A. D., Di Bartolo, B. A., Liu, G., King, P. M., Gibson, R. A., Tan, J. T. M., & Nicholls, S. J. (2020). EICOSAPENTAENOIC ACID AMELIORATES VASCULAR INFLAMMATION: A MECHANISTIC RATIONALE FOR ITS ATHEROPROTECTIVE EFFECTS. Poster session presented at the meeting of JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. Chicago, IL: ELSEVIER SCIENCE INC. 2019 Solly, E., Hourigan, S. T., Mulangala, J., Psaltis, P. J., Di Bartolo, B., Martin, N., . . . Tan, J. T. M. (2019). Inhibition of miR-181c Rescues Diabetes-Impaired Angiogenesis. Poster session presented at the meeting of DIABETES. San Francisco, CA: AMER DIABETES ASSOC.
2019 Fernando, S., Schwarz, N., Sandeman, L., Skoumbourdis, T., Zareh, J., Williamson, A., . . . Psaltis, P. J. (2019). Eukaryotic Elongation Factor 2 Kinase Regulates Cholesterol Uptake by Macrophages via Cd36 Scavenger Receptor Expression. Poster session presented at the meeting of CIRCULATION. Philadelphia, PA: LIPPINCOTT WILLIAMS & WILKINS. 2019 Wong, N. K., Solly, E., Nicholls, S., Psaltis, P., Ng, M. K., Bursill, C. A., & Tan, J. T. (2019). <i>TRIM2</i> an<i>d CREBRF</i> Are Novel Regulators of Angiogenic Functions in Human Coronary Artery Endothelial Cells. Poster session presented at the meeting of CIRCULATION. Philadelphia, PA: LIPPINCOTT WILLIAMS & WILKINS. 2017 Morton, J., Bao, S., Vanags, L., Tsatralis, T., Ridiandries, A., Siu, C. -W., . . . Bursill, C. (2017). Stage-specific Effects of Apolipoprotein (apo) A-I Raising in Atherosclerosis: ApoA-I Suppresses Plaque Size and Preserves High-density Lipoprotein Function in Apo E<SUP>-/-</SUP> Mice With Early Stage <i>But Not</i> Late-stage Disease. Poster session presented at the meeting of CIRCULATION. Anaheim, CA: LIPPINCOTT WILLIAMS & WILKINS. 2016 Tan, J., Hourigan, S., Zhang, J., Wong, N., Tepper, E., Prosser, H., . . . Bursill, C. (2016). miRNA-181c and its putative target TRIM2 mediate the ability of high density lipoproteins to rescue diabetes-impaired angiogenesis. Poster session presented at the meeting of as published in Diabetes. New Orleans, LA: American Diabetes Association. 2015 Tan, J. T. M., Prosser, H. C. G., Dunn, L. L., Vanags, L. Z., Ridiandries, A., Tsatralis, T., . . . Bursill, C. A. (2015). High Density Lipoproteins Rescue Diabetes-Impaired Angiogenesis via Scavenger Receptor-BI and Restoration of VEGF and HIF-1 alpha Stability. Poster session presented at the meeting of DIABETES. Boston, MA: AMER DIABETES ASSOC.
WoS12013 Prosser, H. C., Tan, J. T., Dunn, L. L., Patel, S., Vanags, L. Z., Monger, S., . . . Bursill, C. A. (2013). Multifunctional Regulation of Angiogenesis by High Density Lipoproteins. Poster session presented at the meeting of CIRCULATION. Dallas, TX: LIPPINCOTT WILLIAMS & WILKINS. -
Preprint
Year Citation 2024 Wong, N. K. P., Solly, E., Le, R., Nankivell, V., Mulangala, J., Psaltis, P., . . . Tan, J. T. M. (2024). TRIM2 Selectively Regulates Inflammation-Driven Pathological Angiogenesis without Affecting Physiological Hypoxia-Mediated Angiogenesis.
2024 Nankivell, V., Sandeman, L., Stretton, L., Vidanapathirana, A., Rajora, M., Chen, J., . . . Bursill, C. (2024). Multifunctional biomimetic porphyrin-lipid nanoparticles – novel nanoscale theranostics for atherosclerotic cardiovascular disease.
Diabetes Australia Research Trust 2017 General Grant
“Micromanaging” high density lipoprotein-induced rescue of diabetes-impaired angiogenesis
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2024 Co-Supervisor Deletion of the asialoglycoprotein receptor 1 (ASGR1) to prevent athersclerotic cardiovascular disease Doctor of Philosophy Doctorate Full Time Mr Liam George Stretton -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2019 - 2023 Principal Supervisor MicroRNA-181c-5p - A Novel Therapeutic Target for the Rescue of Diabetes-Impaired Angiogenesis Doctor of Philosophy Doctorate Full Time Miss Emma Louise Solly 2019 - 2023 Co-Supervisor The Role of Endothelial Cell Metabolic Reprogramming in Diabetes impaired Angiogenesis Doctor of Philosophy Doctorate Full Time Miss Khalia Rose Primer 2018 - 2023 Co-Supervisor Investigating the theranostic properties of apoA-I-linked porphyrin-lipid nanoparticles in atherosclerosis Doctor of Philosophy Doctorate Full Time Miss Victoria Ann Nankivell
Connect With Me
External Profiles
